Skip to content
Search resources Open menu

Alcohol Blackout

Treatment and Recovery for Alcohol Problems: What the Evidence Shows

Published

Snap Shot

  • The question: What does research show about how alcohol problems are identified and treated, how often people recover, and how that evidence bears on sentencing, probation, treatment courts, monitoring, and claims of rehabilitation?
  • What the research shows: Brief counseling for risky drinking produces modest average reductions in drinking. For alcohol use disorder, naltrexone and acamprosate have the strongest trial evidence among medications, with small to moderate average effects, and several behavioral treatments perform about as well as one another. In one national survey, many people with an earlier disorder no longer met criteria, some while still drinking at low risk, and some brain measures improve after drinking stops, while studies of cognitive recovery disagree.
  • What it does not show: Treatment studies report group averages, many enrolled mostly men, and some excluded people who were court-ordered. None shows whether a particular person will stay in recovery; a negative test or a period of sobriety does not by itself establish what a person will do later, and relapse does not by itself show that treatment failed.
  • The law: Voluntary intoxication is not a defense in Arizona (A.R.S. § 13-503) and may be considered in courts-martial on specified mental elements (R.C.M. 916(l)(2)); treatment evidence matters most at sentencing and on supervision conditions. Federal courts may not lengthen a prison term to promote rehabilitation (Tapia), and the Ninth Circuit has held that coercing attendance at a religion-based program violates the Establishment Clause (Inouye; later Establishment Clause decisions may bear on its reasoning).
  • Issues for each side: Prosecutors can use the research to show that treatment and monitoring are available and that recovery is measured over time rather than at a single moment; defense counsel can use it to show that alcohol use disorder is treatable and that engagement in treatment is documented. Each side should avoid applying group averages to the person before the court.

Alcohol problems reach courts in several ways. A person charged with an offense committed while drinking may be asked to enter treatment as part of a plea, a diversion agreement, or probation; a defendant may offer a period of sobriety or participation in treatment at sentencing; and a court may order breath testing, transdermal monitoring, or an ignition interlock. Each step rests on assumptions about what treatment does, how long recovery takes, and what a test or a record of attendance can show.

This paper reviews what the research says about identifying alcohol problems, the timing and risks of withdrawal, medications, behavioral treatments, mutual-help programs, rates of recovery, and what happens to the brain after drinking stops. It then describes the evidence on monitoring and court-linked programs and the legal rules that govern treatment as a sentencing or supervision condition. A memory blackout is not a diagnosis. The series’ blackout papers describe memory loss during intoxication; this paper addresses what follows when drinking becomes a problem that people seek, or are directed, to treat.

Screening, Brief Intervention, and Diagnosis

Screening for unhealthy alcohol use means asking short, validated questions in health care or other settings. In an evidence review for the U.S. Preventive Services Task Force, brief screening instruments for adults commonly had sensitivity and specificity between 0.70 and 0.85; the review also found that no study had tested the benefits or harms of screening programs themselves, as distinct from counseling after a positive screen (O’Connor et al., 2018). Pooling 68 counseling trials (36,528 participants), the review found counseling associated with fewer drinks per week (about 1.6 fewer in the 32 trials reporting that outcome) after 6 to 12 months. On that basis the Task Force recommended screening and brief counseling for adults in primary care and concluded that the evidence was insufficient to weigh benefits and harms for adolescents (US Preventive Services Task Force et al., 2018).

A Cochrane review of brief interventions in primary care and emergency settings (69 trials, 33,642 participants) found, in its main analysis of 34 trials, that people who received a brief intervention drank about 20 grams less alcohol per week after a year than people who received minimal or no intervention, roughly one and a half U.S. standard drinks, with substantial differences among trials; both men and women reduced their drinking (Kaner et al., 2018). These are modest average effects among people who were not seeking treatment and say little about people with severe disorders.

Alcohol use disorder is a diagnosis in the American Psychiatric Association’s diagnostic manual (American Psychiatric Association, 2022). The current manual replaced the earlier separate diagnoses of abuse and dependence with a single disorder, added craving, and dropped legal problems as a criterion (Hasin et al., 2013). It lists eleven criteria covering impaired control, social impairment, risky use, and tolerance and withdrawal, and grades severity as mild, moderate, or severe by the number met. A memory blackout is not by itself a criterion, and blackouts occur among drinkers who do not have the disorder, so a reported blackout does not establish a diagnosis for a complainant, an accused, or a witness. In a national survey of 36,309 U.S. adults interviewed in 2012 and 2013, 13.9% met criteria for the disorder in the past year and 29.1% at some time in their lives, with higher rates among men, and only 19.8% of those with a lifetime diagnosis had ever been treated (Grant et al., 2015).

Withdrawal: Timing and Risks

People who have been drinking heavily and regularly can develop withdrawal when they stop or sharply cut back. Mild symptoms such as tremor, sweating, anxiety, and insomnia can begin within hours of the last drink. Seizures are most common in the first 12 to 48 hours, and delirium tremens, the severe form with confusion, hallucinations, and autonomic instability, most often begins 48 to 96 hours after the last drink, although it can start later (National Library of Medicine, n.d.). The clock runs from the last drink, not from the start of other withdrawal symptoms. Withdrawal delirium is a medical emergency; a clinical review describes its recognition and management (Schuckit, 2014), and the American Society of Addiction Medicine publishes a guideline on withdrawal management that addresses assessment of risk and medications (American Society of Addiction Medicine, 2020). Withdrawal is therefore a recognized medical risk during arrest, booking, and custody. The paper Alcohol-Related Psychosis describes how withdrawal delirium bears on memory and reporting; the point here is that supervised withdrawal is part of treatment for people who are physically dependent.

Medications

Three medications are approved in the United States for alcohol use disorder: naltrexone, acamprosate, and disulfiram. A 2023 meta-analysis of 118 randomized trials (20,976 participants) found that the number of people who had to be treated to prevent one from returning to any drinking was 11 for acamprosate (95% confidence interval, 1 to 32) and 18 for oral naltrexone at 50 mg a day (4 to 32), and 11 for return to heavy drinking with oral naltrexone (5 to 41); these are numbers needed to treat, and the abstract consulted does not give the proportions who returned to drinking in each group; acamprosate was associated with more diarrhea and oral naltrexone with more nausea and vomiting than placebo (McPheeters et al., 2023). An earlier meta-analysis of 122 trials reported similar numbers, found no significant difference between acamprosate and naltrexone, and described medications as considerably underused (Jonas et al., 2014). The effects are small to moderate on average, the confidence intervals are wide, and the trials generally paired medication with counseling.

Disulfiram works differently: it produces an unpleasant reaction if the person drinks, so its effect depends on the person’s knowledge of that reaction and often on supervision. A meta-analysis of 22 trials found an advantage over controls in open-label trials but none in blinded trials; the studies were about 89% male (Skinner et al., 2014). Other medications are used off label: in a 12-week trial of 150 people at one site, abstinence was 17.0% with gabapentin at 1,800 mg a day and 4.1% with placebo (Mason et al., 2014), and a Cochrane review of 17 trials (1,818 participants) found moderate-certainty evidence that baclofen probably reduces the risk of relapse slightly (risk ratio 0.87) (Agabio et al., 2023).

The varenicline findings illustrate why single results need care. In a five-site trial of 200 people with alcohol dependence, varenicline, a medication approved for smoking cessation, reduced the percentage of heavy drinking days compared with placebo (Litten et al., 2013). In a later 16-week trial of 131 smokers with alcohol dependence, the overall difference in heavy drinking was not significant, but a treatment-by-sex interaction was: 29% of men taking varenicline (13 of 45) and 6% taking placebo (3 of 47) had no heavy drinking days, while among women the figures were 5% (1 of 19) and 25% (5 of 20) (O’Malley et al., 2018). That is a finding from one trial with 39 women, not an established rule about men and women.

Newer evidence concerns the GLP-1 receptor agonists, medicines used for diabetes and weight management. A 9-week trial of low-dose semaglutide in 48 adults with alcohol use disorder who were not seeking treatment (71% women) reduced alcohol consumed in a laboratory session and craving, but did not change average drinks per day or the number of drinking days (Hendershot et al., 2025). In a 26-week trial of exenatide in 127 treatment-seeking patients, heavy drinking days did not differ significantly from placebo overall, though an exploratory subgroup with obesity showed reductions (Klausen et al., 2022). In a 26-week single-center trial of once-weekly semaglutide in 108 treatment-seeking participants (53 women, 55 men) who had both alcohol use disorder and obesity, all of whom also received cognitive behavioral therapy, heavy drinking days fell by 41.1 percentage points from baseline with semaglutide and 26.4 with placebo, and the authors reported a between-group difference of 13.7 points (95% confidence interval 5.4 to 22.0), which is not the simple subtraction of the two rounded changes (14.7) (Klausen et al., 2026). Because all participants had obesity, the results do not show how the drug performs in people without it, and the evidence base is a few trials.

Behavioral Treatments and Incentive-Based Approaches

Project MATCH, a large federally funded trial, randomly assigned 952 outpatients and 774 people in aftercare (72% and 80% male) to 12 weeks of cognitive behavioral coping skills therapy, motivational enhancement therapy, or twelve-step facilitation. All three groups improved substantially over the following year, and there was little difference in drinking outcomes among them; psychiatric severity was the only attribute with a significant treatment interaction at posttreatment (in the outpatient arm, clients low in psychiatric severity had more abstinent days after twelve-step facilitation than after cognitive behavioral therapy), and two other attributes showed time-dependent matching effects (Project MATCH Research Group, 1997). A meta-analysis of 30 randomized trials of cognitive behavioral therapy for alcohol or other drug use disorders found that it was more effective than no or minimal treatment and, at early follow-up, than nonspecific treatment, but not more effective than another specific therapy (Magill et al., 2019). The research has not identified one behavioral approach that is best for everyone.

Contingency management gives people tangible rewards for verified abstinence. In a trial of 79 outpatients with alcohol dependence and serious mental illness, those who received prizes for urine tests negative for ethyl glucuronide, a metabolite of alcohol, were 3.1 times as likely to submit a negative sample during 12 weeks as controls, and the difference in self-reported drinking persisted at a 3-month follow-up (McDonell et al., 2017). In a trial of 40 treatment-seeking adults, daily payments for negative remote breath tests were associated with 85% days abstinent compared with 38% for a group paid regardless of the results (Koffarnus et al., 2018). Both trials were small, followed participants for a short time, and combined monitoring with incentives; they do not show that monitoring alone, or monitoring with penalties, has the same effect.

Mutual-Help Programs

Alcoholics Anonymous (AA) and similar groups are the most widely used form of support. A Cochrane review of 27 studies (10,565 participants) of AA and professionally delivered twelve-step facilitation, restricted to non-coerced adults, found high-certainty evidence that manualized twelve-step facilitation increased continuous abstinence at 12 months compared with other established treatments such as cognitive behavioral therapy (risk ratio 1.21), based on two studies with 1,936 participants, and found that outcomes on other measures were generally similar to those of other treatments; the authors also reported lower health care costs among participants (Kelly et al., 2020). The review’s evidence concerns clinician-delivered facilitation in structured trials more than unstructured peer attendance, which is largely studied observationally, where attendance may be associated with better outcomes partly because more motivated people attend more. A published commentary has discussed the review’s conclusions (Heather, 2021). In a U.S. survey, mutual-help groups were the most commonly used support among adults who reported having resolved a problem with alcohol or drugs (Kelly et al., 2017). Because the review excluded coerced participants, the research does not say whether mandated attendance produces the same results; constitutional limits on requiring attendance at religion-based programs are described in the law section below.

Recovery, Remission, and Relapse

Many people with alcohol use disorder improve, with or without formal treatment. Among 7,785 U.S. adults whose disorder had begun before the past year, 34.2% still met criteria in the past year, 16.0% were abstinent, 17.9% were drinking at low risk without symptoms, 21.5% were drinking at higher risk without symptoms, and the rest were in other categories; about a quarter achieved abstinent or non-abstinent recovery without treatment, and women and married people had greater odds of recovery (Fan et al., 2019). In a probability-based U.S. survey, 9.1% of adults reported having resolved a problem with alcohol or drugs (Kelly et al., 2017). The National Institute on Alcohol Abuse and Alcoholism has proposed a research definition of recovery as remission from the diagnosis together with cessation of heavy drinking, a definition that does not require abstinence (Hagman et al., 2022). In a prospective study of 442 people beginning a recovery attempt, 34.6% met that definition during a year of follow-up, and ongoing drinking was associated with less stable remission (Kelly et al., 2025).

A return to drinking is reported in follow-up studies of treatment and recovery, and the studies reviewed here describe group outcomes, not a relapse rate for any one person; it does not by itself mean that treatment failed or that a person is unwilling to change. Outcomes unfold over months and years, so a single negative test or a short period of sobriety describes a point in a longer course, and group data do not say how long any one person’s recovery will last.

Hypothetical Example. Consider a hypothetical defendant who, before sentencing for an offense committed while intoxicated, offers records showing 14 months of outpatient treatment, a prescription for naltrexone, and negative breath tests. The prosecution responds that the period is short relative to the defendant’s history and that attendance was a release condition. The research supports the general proposition that treatment and abstinence are associated with better outcomes and that remission is a process; it does not show whether this defendant will remain abstinent, and the records and their limits are for the sentencing court to weigh.

What Happens to the Brain After Drinking Stops

Imaging and cognitive studies suggest partial recovery with abstinence. In a study of 85 people with alcohol dependence scanned at 1 week, 1 month, and 7 months of abstinence, regional gray matter volumes increased over time in most regions examined, though not in the amygdala, and some recovery trajectories were nonlinear (Zou et al., 2018). A review of neuroimaging research concluded that some alterations reverse with sustained abstinence and some do not (Zahr & Pfefferbaum, 2017). On cognition, a meta-analysis of 62 studies found moderate impairment across most cognitive domains in the first year of abstinence and small effects after one year (Stavro et al., 2013), but an updated meta-analysis of 34 studies (2,786 participants) found that deficits, especially in memory, persisted in people abstinent for more than a year, with the authors noting its cross-sectional design and low representation of women (Crowe et al., 2020). The two meta-analyses reach different conclusions about recovery, and neither addresses what any person’s brain was doing during a particular event; the paper Alcohol and the Brain describes the structural findings in more detail.

Monitoring, Supervision, and Treatment Courts

Courts and supervising agencies use several tools. Breath tests, urine tests for ethyl glucuronide, blood tests for phosphatidylethanol, transdermal ankle or wrist monitors, and vehicle ignition interlocks measure different things over different time windows. Transdermal monitors estimate alcohol from ethanol excreted through the skin and lag behind breath alcohol: in a laboratory study of 30 people, a wrist prototype peaked about 54 minutes and an ankle monitor about 120 minutes after peak breath alcohol (Fairbairn & Kang, 2019), and a review of 13 studies found readings moderately to strongly correlated with breath alcohol but less sensitive to low-to-moderate drinking under the manufacturer’s criteria (van Egmond et al., 2020). Urine ethyl glucuronide can be produced by incidental exposure: in 11 volunteers who used an alcohol-based hand sanitizer every five minutes for ten hours on three days, urinary ethyl glucuronide reached 2,001 ng/mL, and the authors concluded that the cutoffs then in use did not separate drinking from such exposure (Reisfield et al., 2011). A 2022 expert consensus addresses phosphatidylethanol testing for abstinence and consumption in clinical and forensic practice (Luginbühl et al., 2022). A result from any of these tests requires interpretation of the method, the time window, and alternative explanations.

Evidence on supervision programs comes mostly from observational designs. South Dakota’s 24/7 Sobriety Project, which requires people arrested for or convicted of alcohol-involved offenses to take breath tests twice a day or wear a continuous monitoring bracelet, with swift, certain, and modest sanctions for violations, was associated at the county level with a 12% reduction in repeat DUI arrests and a 9% reduction in domestic violence arrests, with mixed evidence for crashes (Kilmer et al., 2013). A study of state laws found that requiring ignition interlocks for all drunk-driving offenders was associated with a 7% decrease in the rate of fatal crashes with a blood alcohol concentration above 0.08 (McGinty et al., 2017). A meta-analysis of 215 evaluations of remedial programs for drinking-and-driving offenders found an average 8% to 9% reduction in recidivism among methodologically adequate studies, with combinations of education, counseling, and follow-up contact appearing more effective (Wells-Parker et al., 1995), though it is an older review. These studies describe populations and programs, not the person before the court.

Treatment courts add judicial supervision to treatment. A meta-analysis of 154 evaluations found that adult drug courts were associated with lower recidivism; for the 28 evaluations of DWI courts the average effect was similar in size, but the most rigorous studies did not consistently find reduced recidivism, and the authors called for more experimental evaluations (Mitchell et al., 2012). In a U.S. survey of adults who reported having resolved a problem with alcohol or drugs, those with drug court involvement had higher odds of having used an assisted pathway to recovery (adjusted odds ratio 8.1; alcohol and drug problems combined) (Kelly et al., 2017). The paper Diversion, Mental Health Courts, and Alternatives to Prosecution describes problem-solving courts, their eligibility rules, and the exclusion of many sexual offenses.

Limits of the Evidence

The treatment literature has several recurring limits. Many trials enrolled mostly men (Project MATCH, 72% and 80% male; the disulfiram meta-analysis, about 89%), and women were a minority in several others, so findings for women rest on smaller samples; where a trial tested sex the result was a single-trial finding, as with varenicline, and the cognitive recovery meta-analysis noted low representation of women (Crowe et al., 2020). Several trials were small, single-site, or short, and the GLP-1 findings are from a few trials. Most outcome data come from volunteers who sought treatment, and the Cochrane review of AA excluded people who were coerced. Supervision and court studies are mostly observational, so differences between participants and others can reflect who enters programs. Outcomes are group averages: none of the studies reviewed shows that a particular person will or will not relapse, and a biomarker or monitor result does not by itself show motive, intent, or a person’s state at a past time.

Questions to Ask About This Research

When a treatment record is offered as evidence of recovery, counsel can ask what outcome was measured (attendance, abstinence, remission, function), over what period, and how it was verified. When a medication is cited as effective, counsel can ask how many trials supported the finding, who was enrolled, and whether the effect is a group average with a wide confidence interval (McPheeters et al., 2023). When a negative or positive test is offered, counsel can ask what the test detects, how long after drinking, and what alternative sources are known (Reisfield et al., 2011). When a court program is described as effective, counsel can ask whether the evidence is from randomized or observational designs, and whether the program studied resembles the one at issue (Mitchell et al., 2012). When mutual-help attendance is cited, counsel can ask whether participants chose to attend, since the main review excluded coerced participants (Kelly et al., 2020). These questions are explained in “Reading Research Claims: A Guide for Attorneys” on this site.

Treatment, Recovery, and the Law

Federal and Military Standards

Expert testimony about treatment or recovery is governed by Federal Rule of Evidence 702, as amended December 1, 2023, which requires the proponent to show that it is more likely than not that the testimony rests on sufficient facts or data and reflects a reliable application of reliable methods to the case; Daubert v. Merrell Dow Pharmaceuticals, Inc. (1993) and Kumho Tire Co. v. Carmichael (1999) make the court a gatekeeper for all expert testimony. Military Rule of Evidence 702 tracks the federal rule, and the 2023 amendment took effect in the military rule in 2025 (Joint Service Committee on Military Justice, 2025); practitioners should confirm current text. Voluntary intoxication is not a defense in a court-martial, but evidence of it may raise a reasonable doubt about actual knowledge, specific intent, willfulness, or premeditation (R.C.M. 916(l)(2)), and the paper Voluntary Intoxication, Blackout, and Criminal Responsibility addresses that rule.

At federal sentencing, courts consider the factors in 18 U.S.C. § 3553(a), including the need to provide the defendant with needed medical care or other correctional treatment in the most effective manner (§ 3553(a)(2)(D)); Amendment 836 (effective Nov. 1, 2025) moved departures, including the Chapter 5H policy statements, to Appendix B, and the same facts may be considered for variances under 18 U.S.C. § 3553(a) (U.S. Sentencing Commission, 2025). The Supreme Court has held that a sentencing court may not impose or lengthen a prison term in order to promote a defendant’s rehabilitation, such as by assigning a treatment program (Tapia v. United States, 2011). In courts-martial, the defense may present matters in extenuation and mitigation, which can include a history of alcohol problems and treatment, and the prosecution may present opinion evidence on the accused’s rehabilitative potential (R.C.M. 1001(b)(5), (d)).

Case Example. In Inouye v. Kemna (9th Cir. 2007), a parole officer ordered a parolee into a treatment program that required AA and Narcotics Anonymous meetings, which the parties agreed were based on belief in a higher power, and recommended revoking parole after he refused to participate; parole was then revoked. Reviewing a summary judgment ruling, the Ninth Circuit held that the state may not coerce attendance at such programs, that the law on the point was clearly established, and that the officer was not entitled to qualified immunity, while stating that it did not hold AA to be a religion and did not decide when non-coercive encouragement would be unconstitutional. The case illustrates a legal limit on ordered attendance and does not address whether AA is effective; later Establishment Clause decisions may bear on its reasoning.

Arizona

Arizona Rule of Evidence 702 adopted the Daubert standard in 2012 and was amended effective January 1, 2024, to track the 2023 federal amendment (Ariz. Sup. Ct. Order R-23-0004). Temporary intoxication from the voluntary use of alcohol is not a defense to any criminal act or requisite state of mind (A.R.S. § 13-503). At sentencing, the mitigating circumstances include significantly impaired capacity to appreciate the wrongfulness of conduct or to conform it to the law (A.R.S. § 13-701(E)(2)) and any other relevant factor (A.R.S. § 13-701(E)(6)), under which evidence of treatment and recovery may be offered. For driving under the influence, a court may order alcohol or other drug screening, education or treatment, or evidence-based psychotherapy and may suspend all but one day of a jail sentence if the person completes it; if the person fails to complete it and is not on probation, the court issues an order to show cause (A.R.S. § 28-1381). For an alcohol-involved conviction under that section, the department requires an ignition interlock device, and the court may order the interlock period to extend beyond twelve months (A.R.S. §§ 28-1381, 28-3319). Inouye binds federal courts in Arizona, and an Arizona supervision condition requiring attendance at a religion-based program would raise the same constitutional question.

Special Issues in Legal Practice

The principles described above apply with equal force to every party in a legal proceeding. The science operates the same way regardless of who is asking the questions, and the research summarized here does not by itself favor either side. What differs between the parties is not the science but the vantage point — the particular places where these issues tend to surface, and the particular errors each party is best positioned to guard against. The two summaries below identify those recurring issues. They are offered for orientation, not as litigation strategy; in every case the controlling question is what the evidence in that case will, and will not, support, and the expert’s role is to inform the trier of fact rather than to advocate for either side.

Special Issues for Prosecutors

The research supports several propositions prosecutors can legitimately present. Effective treatments and monitoring tools exist, so a court can reasonably ask what a defendant has done to address an alcohol problem, and because recovery is measured over months and years, a short period of sobriety near sentencing describes a point in a longer course. Records of treatment can be examined for what they show: attendance, attendance under compulsion, or verified abstinence.

The research also counsels caution. A return to drinking does not by itself show that treatment was ineffective; group findings do not show what a particular defendant will do; and the evidence that court-linked programs reduce recidivism is mixed, with the most rigorous DWI court studies not consistently finding an effect. A diagnosis or an earlier episode of treatment does not show that the person did or did not act with a particular mental state on a particular occasion, and the same limits apply to a complainant or witness with a history of alcohol problems or treatment, which does not by itself show that the person’s account is unreliable; whether alcohol affected perception or memory at the time of an event is a separate question.

Special Issues for Defense

The research supports several propositions defense counsel can legitimately present. Alcohol use disorder is a recognized and treatable condition; medications and behavioral treatments show benefits on average in randomized trials; many people recover, including without formal treatment; and some brain measures that change with heavy drinking show partial improvement with abstinence, though meta-analyses disagree on whether cognitive deficits resolve (Stavro et al., 2013; Crowe et al., 2020). A documented record of treatment, medication, verified abstinence, and engagement with supervision is information a court can weigh at sentencing and in setting supervision conditions, and the research supports describing recovery as a process in which setbacks occur.

The research also counsels caution about what treatment evidence shows. Group averages do not show that a particular defendant will remain abstinent, and a short period of sobriety, attendance under a legal requirement, or a negative test does not by itself establish change. Treatment and diagnosis do not alter the rule that voluntary intoxication is not a defense in Arizona or the narrow rule in courts-martial, and biomarker and monitoring results can cut against a defendant as readily as for one. The same limits apply to a complainant or witness with a history of alcohol problems or treatment, which does not by itself show that the person’s account is unreliable; whether alcohol affected perception or memory at the time of an event is a separate question.

This paper is for educational purposes only and is not legal advice. The author is a psychologist, not an attorney; summaries of law are general and must be verified against current authority or with a licensed attorney.

References

Agabio, R., Saulle, R., Rösner, S., & Minozzi, S. (2023). Baclofen for alcohol use disorder. Cochrane Database of Systematic Reviews, 2023(1), Article CD012557. https://doi.org/10.1002/14651858.CD012557.pub3

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787

American Society of Addiction Medicine. (2020). The ASAM clinical practice guideline on alcohol withdrawal management. Journal of Addiction Medicine, 14(3S, Suppl. 1), 1–72. https://doi.org/10.1097/ADM.0000000000000668

Crowe, S. F., Cammisuli, D. M., & Stranks, E. K. (2020). Widespread cognitive deficits in alcoholism persistent following prolonged abstinence: An updated meta-analysis of studies that used standardised neuropsychological assessment tools. Archives of Clinical Neuropsychology, 35(1), 31–45. https://doi.org/10.1093/arclin/acy106

Fairbairn, C. E., & Kang, D. (2019). Temporal dynamics of transdermal alcohol concentration measured via new-generation wrist-worn biosensor. Alcoholism: Clinical and Experimental Research, 43(10), 2060–2069. https://doi.org/10.1111/acer.14172

Fan, A. Z., Chou, S. P., Zhang, H., Jung, J., & Grant, B. F. (2019). Prevalence and correlates of past-year recovery from DSM-5 alcohol use disorder: Results from National Epidemiologic Survey on Alcohol and Related Conditions-III. Alcoholism: Clinical and Experimental Research, 43(11), 2406–2420. https://doi.org/10.1111/acer.14192

Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., & Hasin, D. S. (2015). Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry, 72(8), 757–766. https://doi.org/10.1001/jamapsychiatry.2015.0584

Hagman, B. T., Falk, D., Litten, R., & Koob, G. F. (2022). Defining recovery from alcohol use disorder: Development of an NIAAA research definition. American Journal of Psychiatry, 179(11), 807–813. https://doi.org/10.1176/appi.ajp.21090963

Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., Schuckit, M., & Grant, B. F. (2013). DSM-5 criteria for substance use disorders: Recommendations and rationale. American Journal of Psychiatry, 170(8), 834–851. https://doi.org/10.1176/appi.ajp.2013.12060782

Heather, N. (2021). Let’s not turn back the clock: Comments on Kelly et al., “Alcoholics Anonymous and 12-step facilitation treatments for alcohol use disorder: A distillation of a 2020 Cochrane review for clinicians and policy makers.” Alcohol and Alcoholism, 56(4), 377–379. https://doi.org/10.1093/alcalc/agaa137

Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., McKee, S. A., Fletcher, P. J., Claus, E. D., & Klein, K. R. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405. https://doi.org/10.1001/jamapsychiatry.2024.4789

Joint Service Committee on Military Justice. (2025). Amendments to the Military Rules of Evidence since 1984 (G. E. Maggs, Ed.; 2025 ed.). https://jsc.defense.gov/Portals/99/MRE%20Amendments%202025.pdf

Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., & Garbutt, J. C. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA, 311(18), 1889–1900. https://doi.org/10.1001/jama.2014.3628

Kaner, E. F. S., Beyer, F. R., Muirhead, C., Campbell, F., Pienaar, E. D., Bertholet, N., Daeppen, J. B., Saunders, J. B., & Burnand, B. (2018). Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database of Systematic Reviews, 2018(2), Article CD004148. https://doi.org/10.1002/14651858.CD004148.pub4

Kelly, J. F., Bergman, B., Hoeppner, B. B., Vilsaint, C., & White, W. L. (2017). Prevalence and pathways of recovery from drug and alcohol problems in the United States population: Implications for practice, research, and policy. Drug and Alcohol Dependence, 181, 162–169. https://doi.org/10.1016/j.drugalcdep.2017.09.028

Kelly, J. F., Belisario, K. L., & MacKillop, J. (2025). Prevalence, predictors, correlates, and dynamic changes in the NIAAA-defined “recovery” definition. Alcohol, Clinical and Experimental Research, 49(11), 2579–2591. https://doi.org/10.1111/acer.70172

Kelly, J. F., Humphreys, K., & Ferri, M. (2020). Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database of Systematic Reviews, 2020(3), Article CD012880. https://doi.org/10.1002/14651858.CD012880.pub2

Kilmer, B., Nicosia, N., Heaton, P., & Midgette, G. (2013). Efficacy of frequent monitoring with swift, certain, and modest sanctions for violations: Insights from South Dakota’s 24/7 Sobriety Project. American Journal of Public Health, 103(1), e37–e43. https://doi.org/10.2105/AJPH.2012.300989

Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A. Ø., Zeeman, V. A., Johannsen, C. F., Lee, A., Thomsen, G. K., Macoveanu, J., Fisher, P. M., Gillum, M. P., Jørgensen, N. R., Bergmann, M. L., Poulsen, H. E., Becker, U., Holst, J. J., Benveniste, H., Volkow, N. D., . . . Fink-Jensen, A. (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 7(19), Article e159863. https://doi.org/10.1172/jci.insight.159863

Klausen, M. K., Justesen, S. K., Pedersen, J. N., Rasmussen, L., Jensen, A., Jensen, M. E., Knorr, U. B., Bergmann, M. L., Holst, J. J., Hartmann, B., Koob, G. F., Benveniste, H., Volkow, N. D., Ekstrøm, C. T., Knudsen, G. M., Vilsbøll, T., & Fink-Jensen, A. (2026). Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial. The Lancet, 407(10540), 1687–1698. https://doi.org/10.1016/S0140-6736(26)00305-3

Koffarnus, M. N., Bickel, W. K., & Kablinger, A. S. (2018). Remote alcohol monitoring to facilitate incentive-based treatment for alcohol use disorder: A randomized trial. Alcoholism: Clinical and Experimental Research, 42(12), 2423–2431. https://doi.org/10.1111/acer.13891

Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., Kampman, K., Brunette, M. F., Strain, E. C., Tiouririne, N. A., Ransom, J., Scott, C., Stout, R., & NCIG (National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group) Study Group. (2013). A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. Journal of Addiction Medicine, 7(4), 277–286. https://doi.org/10.1097/ADM.0b013e31829623f4

Luginbühl, M., Wurst, F. M., Stöth, F., Weinmann, W., Stove, C. P., & Van Uytfanghe, K. (2022). Consensus for the use of the alcohol biomarker phosphatidylethanol (PEth) for the assessment of abstinence and alcohol consumption in clinical and forensic practice (2022 Consensus of Basel). Drug Testing and Analysis, 14(10), 1800–1802. https://doi.org/10.1002/dta.3340

Magill, M., Ray, L., Kiluk, B., Hoadley, A., Bernstein, M., Tonigan, J. S., & Carroll, K. (2019). A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. Journal of Consulting and Clinical Psychology, 87(12), 1093–1105. https://doi.org/10.1037/ccp0000447

Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014). Gabapentin treatment for alcohol dependence: A randomized clinical trial. JAMA Internal Medicine, 174(1), 70–77. https://doi.org/10.1001/jamainternmed.2013.11950

McDonell, M. G., Leickly, E., McPherson, S., Skalisky, J., Srebnik, D., Angelo, F., Vilardaga, R., Nepom, J. R., Roll, J. M., & Ries, R. K. (2017). A randomized controlled trial of ethyl glucuronide-based contingency management for outpatients with co-occurring alcohol use disorders and serious mental illness. American Journal of Psychiatry, 174(4), 370–377. https://doi.org/10.1176/appi.ajp.2016.16050627

McGinty, E. E., Tung, G., Shulman-Laniel, J., Hardy, R., Rutkow, L., Frattaroli, S., & Vernick, J. S. (2017). Ignition interlock laws: Effects on fatal motor vehicle crashes, 1982–2013. American Journal of Preventive Medicine, 52(4), 417–423. https://doi.org/10.1016/j.amepre.2016.10.043

McPheeters, M., O’Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023). Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis. JAMA, 330(17), 1653–1665. https://doi.org/10.1001/jama.2023.19761

Mitchell, O., Wilson, D. B., Eggers, A., & MacKenzie, D. L. (2012). Assessing the effectiveness of drug courts on recidivism: A meta-analytic review of traditional and non-traditional drug courts. Journal of Criminal Justice, 40(1), 60–71. https://doi.org/10.1016/j.jcrimjus.2011.11.009

National Library of Medicine. (n.d.). Delirium tremens. MedlinePlus. Retrieved November 11, 2026, from https://medlineplus.gov/ency/article/000766.htm

O’Connor, E. A., Perdue, L. A., Senger, C. A., Rushkin, M., Patnode, C. D., Bean, S. I., & Jonas, D. E. (2018). Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 320(18), 1910–1928. https://doi.org/10.1001/jama.2018.12086

O’Malley, S. S., Zweben, A., Fucito, L. M., Wu, R., Piepmeier, M. E., Ockert, D. M., Bold, K. W., Petrakis, I., Muvvala, S., Jatlow, P., & Gueorguieva, R. (2018). Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: A randomized clinical trial. JAMA Psychiatry, 75(2), 129–138. https://doi.org/10.1001/jamapsychiatry.2017.3544

Project MATCH Research Group. (1997). Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. Journal of Studies on Alcohol, 58(1), 7–29. https://doi.org/10.15288/jsa.1997.58.7

Reisfield, G. M., Goldberger, B. A., Crews, B. O., Pesce, A. J., Wilson, G. R., Teitelbaum, S. A., & Bertholf, R. L. (2011). Ethyl glucuronide, ethyl sulfate, and ethanol in urine after sustained exposure to an ethanol-based hand sanitizer. Journal of Analytical Toxicology, 35(2), 85–91. https://doi.org/10.1093/anatox/35.2.85

Schuckit, M. A. (2014). Recognition and management of withdrawal delirium (delirium tremens). New England Journal of Medicine, 371(22), 2109–2113. https://doi.org/10.1056/NEJMra1407298

Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H. J. (2014). Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS ONE, 9(2), Article e87366. https://doi.org/10.1371/journal.pone.0087366

Stavro, K., Pelletier, J., & Potvin, S. (2013). Widespread and sustained cognitive deficits in alcoholism: A meta-analysis. Addiction Biology, 18(2), 203–213. https://doi.org/10.1111/j.1369-1600.2011.00418.x

US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Jr., Kemper, A. R., Kubik, M., Landefeld, C. S., Mangione, C. M., Silverstein, M., Simon, M. A., Tseng, C.-W., & Wong, J. B. (2018). Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA, 320(18), 1899–1909. https://doi.org/10.1001/jama.2018.16789

U.S. Sentencing Commission. (2025). Amendments in brief: Simplification [Amendment effective November 1, 2025]. https://www.ussc.gov/sites/default/files/pdf/amendment-process/amendments-in-brief/AIB_2025-simplification.pdf

van Egmond, K., Wright, C. J. C., Livingston, M., & Kuntsche, E. (2020). Wearable transdermal alcohol monitors: A systematic review of detection validity, and relationship between transdermal and breath alcohol concentration and influencing factors. Alcoholism: Clinical and Experimental Research, 44(10), 1918–1932. https://doi.org/10.1111/acer.14432

Wells-Parker, E., Bangert-Drowns, R., McMillen, R., & Williams, M. (1995). Final results from a meta-analysis of remedial interventions with drink/drive offenders. Addiction, 90(7), 907–926. https://doi.org/10.1111/j.1360-0443.1995.tb03500.x

Zahr, N. M., & Pfefferbaum, A. (2017). Alcohol’s effects on the brain: Neuroimaging results in humans and animal models. Alcohol Research: Current Reviews, 38(2), 183–206. https://doi.org/10.35946/arcr.v38.2.04

Zou, X., Durazzo, T. C., & Meyerhoff, D. J. (2018). Regional brain volume changes in alcohol-dependent individuals during short-term and long-term abstinence. Alcoholism: Clinical and Experimental Research, 42(6), 1062–1072. https://doi.org/10.1111/acer.13757

Legal Authorities

Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993).

Inouye v. Kemna, 504 F.3d 705 (9th Cir. 2007).

Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999).

Tapia v. United States, 564 U.S. 319 (2011).

18 U.S.C. § 3553(a).

Ariz. Rev. Stat. Ann. §§ 13-503, 13-701(E), 28-1381, 28-3319.

Fed. R. Evid. 702.

Mil. R. Evid. 702, 1102.

Ariz. R. Evid. 702.

Ariz. Sup. Ct. Order R-23-0004 (amending Ariz. R. Evid. 702, effective Jan. 1, 2024).

Rules for Courts-Martial 916(l)(2), 1001(b)(5), 1001(d).

Related topic papers: Alcohol and the Brain · Alcohol-Related Psychosis · PTSD and Substance Use Disorders · Voluntary Intoxication, Blackout, and Criminal Responsibility · Breath Versus Blood Testing: Partition Ratios, Serum Results, and Hospital Records · Self-Reports of Drinking: Underestimation and Counting Drinks

Related topics from Arizona Forensic Services: Courts-Martial